Anixa Biosciences is trading at $3.82 (+6.11%) after rising before the August 28, 2026 open, with no confirmed company-specific catalyst identified.

  • Recent company releases highlighted upcoming healthcare conferences and clinical-development updates, but none directly explains the move.
  • Broader indexes were nearly flat, providing no clear market-wide explanation; confidence remains low pending additional filings or announcements.